scientific reports

Check for updates

OPEN

Correction to: Polyphenols journey through blood-brain barrier towards neuronal protection

Published online: 18 August 2021

I. Figueira, G. Garcia, R. C. Pimpão, A. P. Terrasso, I. Costa, A. F. Almeida, L. Tavares, T. F. Pais, P. Pinto, M. R. Ventura, A. Filipe, G. J. McDougall, D. Stewart, K. S. Kim, I. Palmela, D. Brites, M. A. Brito, C. Brito & C. N. Santos

Correction to: *Scientific Reports* https://doi.org/10.1038/s41598-017-11512-6, published online 13 September 2017

The original version of this Article contained an error in Figure 3a where the oxidative lesion applied was incorrect,

"300 μM t-BHP"

now reads:

"300 μM H_2O_2"

Moreover, the original version of this Article also contained an error in Figure 3b where the glutamate excitotoxicity was incorrect,

"300 μM H_2O_2"

now reads:

"100 μM glutamate"

The figure legend was correct at the time of publication. The original Figure 3 and accompanying legend appear below.

The original Article has been corrected.



Figure 3. Cytoprotective potential of Cat-sulf and Pyr-sulf. (**a**) HBMEC line submitted to oxidative stress (300 µM H_2O_2); (**b**) primary mouse cerebellar granule cells exposed to glutamate excitotoxicity (100 µM glutamate); (**c**) 3D aggregates containing neurons and astrocytes exposed to oxidative injury (300 µM *t*-BHP). Cells were pre-incubated with 5 µM of each bioavailable polyphenol metabolite for 24 h and then injured with the respective lesion. Cell viability was assessed and is presented as percentage relatively to control. Statistical differences are denoted as $^{***}p < 0.001$, $^{**}p < 0.01$ and $^{*}p < 0.05$ relatively to control and as $^{###}p < 0.001$, $^{##}p < 0.01$ and $^{#}p < 0.05$ relatively to each lesion (H_2O_2, glutamate or *t*-BHP). (**d–f**) Alterations in protein markers of the neuronal (β-III tubulin) and astrocytic (GFAP) population of 3D aggregates towards the *t*-BHP lesion without and with pre-incubation with idebenone (Ide), a control drug, and with Pyr-sulf. (**d**) Representative western blot and (**e**) β-III tubulin and (**f**) GFAP fold changes in protein levels normalized to GAPDH. Statistical differences are denoted as $^{***}p < 0.001$, $^{**}p < 0.01$ and $^{*}p < 0.05$ relatively to control and as $^{###}p < 0.001$ relatively to *t*-BHP. Western blots were analyzed under the same experimental conditions. Data are presented as the means ± SD, n = 3.